| Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial | 09/13 10:00 | globenewswire.com |
| Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 | 09/09 07:30 | globenewswire.com |
| Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 08/12 07:01 | globenewswire.com |
| Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers | 07/09 07:30 | globenewswire.com |
| Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | 06/03 07:01 | globenewswire.com |
| Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference | 05/09 07:01 | globenewswire.com |
| Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 05/07 07:01 | globenewswire.com |
| Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting | 04/09 16:35 | globenewswire.com |
| Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting | 03/05 16:45 | globenewswire.com |
| Prelude Therapeutics to Participate in Barclays Global Healthcare Conference | 02/29 16:05 | globenewswire.com |